Mike Yeadon, PhD.PULMONOLOGY SCIENTIFIC ADVISORY BOARD
President and CEO, Ziarco, UK
Dr. Yeadon attended the University of Surrey in Guildford, U.K, where he received his PhD with thesis work in the respiratory field, and a BSc, First Class, with Joint Honours, in Biochemistry and Toxicology. He worked at the Wellcome Research Labs with Salvador Moncada with a research focus on airway hyper-responsiveness and effects of pollutants including ozone, as well as working in drug discovery of 5-LO, COX, NO and lung inflammation. With the help of colleagues, he was the first to detect exhaled NO in animals and later to induce NOS in lung via allergic triggers.
Dr. Yeadon is a co-founder and CEO of Ziarco. He is an Allergy & Respiratory therapeutic area expert, developed out of deep knowledge of biology & therapeutics and is an innovative drug discoverer, with over 25 years of experience in drug discovery and development. Prior to consulting as an independent, he was Vice President and Chief Scientific Officer of the A&R Research Unit of Pfizer. At Pfizer, Dr. Yeadon was responsible for target selection and the progress into humans of new molecules, leading teams of up to 200 staff across all disciplines and won an Achievement Award for productivity in 2008. Under his leadership the unit invented oral and inhaled NCEs which delivered positive clinical proofs of concept in asthma, allergic rhinitis and COPD. He led productive external collaborations and was involved in product and device licensing. Since leaving Pfizer in 2011, Dr. Yeadon has advised more than 20 private & public biopharma companies, investors & analysts and is currently an independent board member of Antegrin Therapeutics.
Ziarco is a clinical stage biotechnology company which owns multiple valuable and competitively-placed assets that have broad therapeutic potential in inflammatory and allergic diseases. Current focus is on chronic, inflammatory skin diseases, specifically atopic dermatitis and psoriasis. ZPL-3893787 is a once-daily oral antagonist of the most recently characterised histamine receptor, H4R, which we will advance into Phase 2 patient studies during 2015. ZPL-5212372 is a potent, long-acting, topical inhibitor of cPLA2, which is anticipated to reach patients in 2016. Ziarco’s programmes are distinctive yet share key over-arching characteristics: new mechanism small molecules which will safely suppress steroid-unresponsive inflammation and represent significant advances in medical therapy. Ziarco’s approach is to advance their programmes in therapeutic indications where evidence of differentiation can be clearly demonstrated at early times during clinical development.